Form 8-K

8-K — ORTHOPEDIATRICS CORP

Accession: 0001425450-26-000091

Filed: 2026-10-27

Period: 2026-10-27

CIK: 0001425450

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — kids-20261027.htm (Primary)

EX-99.1 (kidsq32026earningsrelease.htm)

GRAPHIC (footer.jpg)

GRAPHIC (header.jpg)

GRAPHIC (logo.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: kids-20261027.htm · Sequence: 1

kids-20261027

0001425450FALSE00014254502023-05-012023-05-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

______________________

Date of Report (Date of earliest event reported): October 27, 2026

OrthoPediatrics Corp.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-38242 26-1761833

(Commission File Number) (I.R.S. Employer Identification Number)

2850 Frontier Drive

Warsaw, Indiana

46582

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (574) 268-6379

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $0.00025 par value per share KIDS Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨

Item 2.02. Results of Operations and Financial Condition.

On October 27, 2026, OrthoPediatrics Corp. issued a press release announcing its earnings for the quarter ended September 30, 2026 and making other disclosures. The press release (including the accompanying unaudited condensed consolidated financial statements as of and for the quarter ended September 30, 2026, and other financial data) is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1

Press release dated October 27, 2026 issued by OrthoPediatrics Corp.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

* * * * * *

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OrthoPediatrics Corp.

Date: October 27, 2026 By: /s/ Daniel J. Gerritzen

Daniel J. Gerritzen,

General Counsel and Secretary

- 2 -

EX-99.1

Filename: kidsq32026earningsrelease.htm · Sequence: 2

Document

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance

Record Third Quarter 2026 Revenue of $72.7 Million, Up 19% Year-over-Year

WARSAW, Ind., October 27, 2026 -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 and Recent Business Highlights

•Helped nearly 42,000 children in the third quarter of 2026

•Generated new record high total revenue of $72.7 million for the third quarter of 2026, up 19% from $61.2 million in the third quarter of 2025; domestic revenue increased 19% and international revenue increased 18% in the quarter

•Grew worldwide Trauma & Deformity revenue 19% in the third quarter of 2026 compared to the third quarter of 2025, and grew Scoliosis revenue 18% in the third quarter of 2026 compared to the third quarter of 2025

•Achieved record adjusted EBITDA of $6.9 million in the third quarter of 2026, compared to $6.2 million in the third quarter of 2025

•Generated free cash flow of $1.6 million in the third quarter of 2026, a $5.0 million improvement as compared to $3.4 million of usage in the prior year period

•Announced full market release of 3P™ Pediatric Plating Platform® Hip System, and the PediHip Rigid Brace

•Continued to expand the portfolio with multiple new products, including FDA clearance and subsequent limited launch of PNP Retrograde, the limited launch of OPSB® Knee 'TractorFIX, and the limited launch of 3P™ Pediatric Plating Platform® Small Mini

•Increased full year 2026 revenue guidance to $270.0 million to $273.0 million from its prior range of $265.0 million to $269.0 million, representing growth of 14% to 16% compared to prior year

“In the third quarter, we continued to build on the momentum in our business, gaining share in Trauma and Deformity and Scoliosis globally, and continued substantial progress with our OPSB strategy. This quarter, we not only drove revenue growth, but we continued to improve profitability, and generated positive free cash flow. We remain confident in our ability to continue to drive these metrics forward," said David Bailey, President & CEO of OrthoPediatrics. "Our innovation super cycle is an important part of that opportunity, with a strong pipeline of new products coming over the next several years that are expected to deliver higher value and improved capital efficiency. We believe these launches will be an important driver of our financial performance as we bring new solutions to more surgeons and hospitals. There are still significant unmet needs in pediatric orthopedics, and we believe OrthoPediatrics is well positioned to capitalize on that opportunity. Our focus remains on growing the business, improving our operating performance, and achieving breakeven or better free cash flow on an annual basis in 2026 and beyond while continuing to deliver innovative solutions for children.”

Third Quarter 2026 Financial Results

Total revenue for the third quarter of 2026 was $72.7 million, a 19% increase compared to $61.2 million for the same period last year. U.S. revenue for the third quarter of 2026 was $57.9 million, a 19% increase compared to $48.7 million for the same period last year, representing 80% of total revenue. The increase in revenue in the third quarter of 2026 was driven primarily by growth in global Trauma and Deformity and OPSB products. International revenue for the third quarter of 2026 was $14.8 million, an 18% increase compared to $12.5 million for the same period last year, representing 20% of total revenue. Growth in the quarter was primarily driven by increased procedure volumes.

Trauma and Deformity revenue for the third quarter of 2026 was $52.6 million, a 19% increase compared to $44.1 million for the same period last year. This growth was driven primarily by numerous product lines, specifically our Cannulated Screws, PNP Femur, PediPlates, the addition of 3P Hip, as well as continued OPSB growth. Scoliosis revenue was $19.2 million, an 18% increase compared to $16.3 million for the third quarter of 2025. The increase was due to increased revenue generated from VerteGlide and Response. Sports Medicine/Other revenue for the third quarter of 2026 was $0.9 million, a 2% increase compared to $0.8 million for the same period last year.

Gross profit for the third quarter of 2026 was $54.0 million, a 19% increase compared to $45.3 million for the same period last year. Gross profit margin for the third quarter of 2026 was 74%, consistent with the same period last year.

Total operating expenses for the third quarter of 2026 were $58.2 million, a 6% increase compared to $54.7 million for the same period last year. The increase was mainly driven by increased sales commission expense as well as additional personnel supporting clinic expansions and small-scale acquisitions.

Sales and marketing expenses increased $4.4 million, or 24%, to $23.1 million in the third quarter of 2026. The increase was driven primarily by increased sales commission expenses and an overall increase in volume of units sold.

Research and development expenses increased $0.1 million, or 6%, to $2.5 million in the third quarter of 2026. The increase was primarily due to ongoing product development during the third quarter of 2026.

General and administrative expenses increased $2.9 million, or 10%, to $32.0 million in the third quarter of 2026. The increase was primarily due to the additional personnel supporting clinic expansions and small-scale acquisitions.

Intangible asset impairment recorded during the third quarter of 2026 was $0.6 million as a result of completing our annual impairment analysis for our tradenames, where we determined the fair value of the ApiFix and MedTech trademark assets were below the carrying value. We recorded an impairment charge to reduce the carrying amount of the intangible assets to their estimated fair value.

Total other expense was $1.8 million for the third quarter of 2026, compared to other expense of $2.5 million for the same period last year. The change was primarily driven by a $0.8 million non-cash fair value adjustment of contingent consideration, additional interest expense in 2026 compared to 2025, as well as changes in foreign exchange gains and losses. Foreign exchange losses were primarily driven by changes in the Euro exchange rate, as the Euro declined in value during the three months ended September 30, 2026, compared to Euro appreciation for the three months ended September 30, 2025.

Net loss for the third quarter of 2026 was $5.9 million, compared to $11.8 million for the same period last year. Net loss per share for the period was $0.25 per basic and diluted share, compared to $0.50 per basic and diluted share for the same period last year.

Adjusted EBITDA for the third quarter of 2026 was $6.9 million as compared to $6.2 million for the third quarter of 2025.

Weighted average basic and diluted shares outstanding for the three months ended September 30, 2026, was 24,153,621 shares.

As of September 30, 2026, cash, cash equivalents, short-term investments and restricted cash were $44.9 million compared to $62.9 million as of December 31, 2025. Free cash flow generated in the third quarter of 2026 was $1.6 million, a 147% improvement as compared to $3.4 million used in the third quarter of 2025. Increased adjusted EBITDA, lower sets deployed and improved working capital metrics all contributed to the year-over-year improvement.

Full Year 2026 Financial Guidance

For the full year of 2026, the Company is increasing its revenue guidance to $270.0 million to $273.0 million from its prior range of $265.0 million to $269.0 million, representing growth of 14% to 16% over 2025 revenue. The Company reiterated it expects annual set deployment to be approximately $10.0 million, expects adjusted EBITDA of approximately $25.0 million, and expects to achieve breakeven free cash flow in 2026.

Conference Call

OrthoPediatrics will host a conference call on Tuesday, October 27, 2026, at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for replay for at least 90 days after the event.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of U.S. federal securities laws. You

can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect,"

"plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential,” "objective," "would" and other similar expressions. Forward-looking statements involve risks and uncertainties, many of which are beyond OrthoPediatrics’ control. Important factors could cause actual results to differ materially from those in the forward-looking statements, including, among others: the risks related to widespread health emergencies, such as respiratory syncytial virus, the impact such pandemics, epidemics and infectious disease outbreaks may have on the demand for our products, and our ability to respond to the related challenges; and the risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics’ Annual Report on Form 10-K filed with the SEC on March 4, 2026, as updated and supplemented by our other SEC reports filed from time to time. Forward-looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws.

Use of Non-GAAP Financial Measures

This press release includes certain non-GAAP financial measures, such as free cash flow, adjusted diluted (loss) earnings per share and Adjusted EBITDA, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Free cash flow, which we reconcile to "Net cash provided by (used in) operating activities" is cash flow from operations reduced by "Capital expenditures". Adjusted loss per share in this press release represents diluted loss per share on a GAAP basis, excluding intangible asset impairment, fair value adjustment of contingent consideration, restructuring charges, tariffs, European Union Medical Device Regulation fees increase, acquisition-related costs, and minimum purchase commitment costs. We believe that providing the non-GAAP diluted loss per share excluding these expenses, as well as the GAAP measures, assists our investors because such expenses are not reflective of our ongoing operating results. Adjusted EBITDA in this release represents net loss, plus interest expense, net plus other expense (income), net plus income tax charge (benefit), depreciation and amortization, intangible asset impairment, stock-based compensation expense, fair value adjustment of contingent consideration, restructuring charges, tariffs, European Union Medical Device Regulation

fees increase, acquisition-related costs, and the cost of minimum purchase commitments. The fair value adjustment of contingent consideration is associated with our estimates of the value of earn-outs in connection with certain acquisitions. The Company believes the non-GAAP measures provided in this earnings release enable it to further and more consistently analyze the period-to-period financial performance of its core business operating performance. Management uses these metrics as a measure of the Company’s operating performance and for planning purposes, including financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. Free cash flow is a non-GAAP financial measure and has limitations because it does not represent the cash flow available for management's use as it does not reflect capital expenditures which will likely recur in the future. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating these non-GAAP measures, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP free cash flow, diluted loss per share or Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using these adjusted measures on a supplemental basis. The Company’s definition of these measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules below contain reconciliations of Net cash used in operating activities to Free cash flow (Non-GAAP), GAAP diluted loss per share to non-GAAP diluted loss per share and net loss to non-GAAP Adjusted EBITDA.

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 95 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com.

Investor Contact

Philip Trip Taylor

Gilmartin Group

philip@gilmartinir.com

415-937-5406

ORTHOPEDIATRICS CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited) (In Thousands, Except Share Data)

September 30, 2026 December 31, 2025

ASSETS

Current assets:

Cash

$ 17,141 $ 19,556

Restricted cash 710 2,064

Short-term investments 27,088 41,295

Accounts receivable - trade, net of allowances of $1,619 and $1,501, respectively

59,543 53,838

Inventories, net

141,864 133,790

Prepaid expenses and other current assets

6,895 5,876

Total current assets

253,241 256,419

Property and equipment, net 46,941 49,555

Other assets:

Amortizable intangible assets, net 61,668 64,802

Goodwill

118,586 109,269

Other intangible assets

12,200 12,909

Other non-current assets

16,451 15,676

Total other assets

208,905 202,656

Total assets $ 509,087 $ 508,630

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable - trade

$ 24,485 $ 18,786

Accrued compensation and benefits

16,657 13,693

Current portion of long-term debt with affiliate

174 170

Current portion of acquisition installment payable

1,691 2,194

Other current liabilities

12,625 11,354

Total current liabilities

55,632 46,197

Long-term liabilities:

Long-term term loan

48,560 48,189

Long-term convertible note

48,961 48,486

Long-term debt with affiliate, net of current portion

152 283

Other long-term debt, net of current portion 515 2,862

Acquisition installment payable, net of current portion

3,053 2,898

Deferred income taxes 3,140 3,582

Other long-term liabilities 9,724 9,537

Total long-term liabilities

114,105 115,837

Total liabilities 169,737 162,034

Stockholders' equity:

Common stock, $0.00025 par value; 50,000,000 shares authorized; 26,115,126 shares and 25,093,792 shares issued as of September 30, 2026 and December 31, 2025, respectively

7 6

Additional paid-in capital

637,299 622,325

Accumulated deficit

(298,992) (275,212)

Accumulated other comprehensive income (loss)

1,036 (523)

Total stockholders' equity

339,350 346,596

Total liabilities and stockholders' equity $ 509,087 $ 508,630

ORTHOPEDIATRICS CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In Thousands, Except Share and Per Share Data)

Three Months Ended September 30, Nine Months Ended September 30,

2026 2025 2026 2025

Net revenue $ 72,661 $ 61,250 $ 202,530 $ 174,743

Cost of revenue 18,685 15,976 52,798 47,188

Gross profit 53,976 45,274 149,732 127,555

Operating expenses:

Sales and marketing

23,096 18,652 62,860 54,327

General and administrative

32,029 29,155 95,866 89,878

Intangible asset impairment

611 2,268 611 2,268

Restructuring — 2,294 1 5,305

Research and development

2,465 2,333 7,021 6,843

Total operating expenses

58,201 54,702 166,359 158,621

Operating loss (4,225) (9,428) (16,627) (31,066)

Other expense (income):

Interest expense, net

2,617 1,822 7,248 4,064

Fair value adjustment of contingent consideration

(814) — (814) —

Other expense (income), net

11 648 765 (5,705)

Total other expense (income), net

1,814 2,470 7,199 (1,641)

Net loss before income taxes $ (6,039) $ (11,898) (23,826) (29,425)

Income tax (benefit) charge (109) (125) (46) 120

Net loss $ (5,930) $ (11,773) $ (23,780) $ (29,545)

Weighted average common stock - basic and diluted 24,153,621 23,565,779 23,964,171 23,420,158

Net loss per share – basic and diluted

$ (0.25) $ (0.50) $ (0.99) $ (1.26)

ORTHOPEDIATRICS CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)(In Thousands)

Nine Months Ended September 30,

2026 2025

OPERATING ACTIVITIES

Net loss $ (23,780) $ (29,545)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

Goodwill and other intangible asset impairments

611 4,163

Depreciation and amortization

17,048 15,517

Stock-based compensation

12,592 13,362

Fair value adjustment of contingent consideration

(814) —

Accretion of acquisition installment payable

365 105

Deferred income taxes (393) 120

Non-cash other 695 (88)

Changes in certain operating assets and liabilities, net of acquisitions:

Accounts receivable - trade

(4,717) (8,270)

Inventories

(4,922) (7,893)

Prepaid expenses and other current assets

(579) 176

Accounts payable - trade

5,299 (1,961)

Accrued expenses and other liabilities

1,816 790

Other

(1,074) (1,675)

Net cash provided by (used in) operating activities 2,147 (15,199)

INVESTING ACTIVITIES

Other acquisitions, including clinics, net of cash acquired (8,410) (8,852)

Sale of short-term marketable securities 15,000 —

Investment in private companies and purchases of licenses (810) (2,007)

Purchase of short-term marketable securities — (15,000)

Purchases of property and equipment (8,716) (10,511)

Net cash used in investing activities (2,936) (36,370)

FINANCING ACTIVITIES

Proceeds from issuance of debt — 25,000

Payment on debt issuance costs (289) —

Payments on mortgage notes (127) (119)

Payments on acquisition notes (2,464) (489)

Net cash (used in) provided by financing activities (2,880) 24,392

Effect of exchange rate changes on cash, cash equivalents and restricted cash (100) 284

NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH (3,769) (26,893)

Cash, cash equivalents and restricted cash, beginning of year $ 21,620 $ 45,777

Cash, cash equivalents and restricted cash, end of period $ 17,851 $ 18,884

2026 2025

SUPPLEMENTAL DISCLOSURES

Cash paid for interest $ 5,646 $ 4,562

Transfer of instruments between property and equipment and inventory $ 2,611 $ 1,881

Right-of-use assets obtained in exchange for lease liabilities $ 2,838 $ 4,812

Issuance of common shares to settle an obligation with a vendor $ — $ 1,261

Issuance of common shares for MedTech installment $ 2,398 $ 226

Issuance of common shares in connection with acquisitions $ 1,656 $ —

Issuance of common shares in connection with Boston O&P acquisition $ — $ 233

Capital contribution associated with reclassification of MedTech liability to equity $ — $ 2,062

ORTHOPEDIATRICS CORP.

NET REVENUE BY GEOGRAPHY AND PRODUCT CATEGORY

(Unaudited)

(In Thousands)

Three Months Ended September 30, Nine Months Ended September 30,

Product sales by geographic location: 2026 2025 2026 2025

U.S.

$ 57,890 $ 48,718 $ 157,990 $ 137,757

International

14,771 12,532 44,540 36,986

Total

$ 72,661 $ 61,250 $ 202,530 $ 174,743

Three Months Ended September 30, Nine Months Ended September 30,

Product sales by category: 2026 2025 2026 2025

Trauma and deformity

$ 52,623 $ 44,143 $ 148,300 $ 123,665

Scoliosis

19,172 16,261 51,490 48,447

Sports medicine/other

866 846 2,740 2,631

Total

$ 72,661 $ 61,250 $ 202,530 $ 174,743

ORTHOPEDIATRICS CORP.

RECONCILIATION OF NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES

TO FREE CASH FLOW

(Unaudited)

(In Thousands)

Three Months Ended September 30, Nine Months Ended September 30,

2026 2025 2026 2025

Net cash provided by (used in) operating activities (GAAP)

$ 4,506 $ (581) $ 2,147 $ (15,199)

Less: Capital expenditures

(2,911) (2,839) (8,716) (10,511)

Free cash flow (non-GAAP)

$ 1,595 $ (3,420) $ (6,569) $ (25,710)

ORTHOPEDIATRICS CORP.

RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA

(Unaudited)

(In Thousands)

Three Months Ended September 30, Nine Months Ended September 30,

2026 2025 2026 2025

Net loss $ (5,930) $ (11,773) $ (23,780) $ (29,545)

Interest expense, net

2,617 1,822 7,248 4,064

Other expense (income), net

11 648 765 (5,705)

Income tax charge (benefit) (109) (125) (46) 120

Depreciation and amortization

5,621 5,299 17,048 15,517

Intangible asset impairment 611 2,268 611 2,268

Stock-based compensation

4,419 4,251 12,592 13,362

Fair value adjustment of contingent consideration (814) — (814) —

Restructuring charges — 2,294 1 5,305

Tariffs 178 306 570 954

European Union Medical Device Regulation fees increase — — — 109

Acquisition-related costs

342 943 1,691 2,532

Minimum purchase commitment cost — 261 — 960

Adjusted EBITDA $ 6,946 $ 6,194 $ 15,886 $ 9,941

ORTHOPEDIATRICS CORP.

RECONCILIATION OF DILUTED LOSS PER SHARE TO NON-GAAP ADJUSTED DILUTED LOSS PER SHARE

(Unaudited)

Three Months Ended September 30, Nine Months Ended September 30,

2026 2025 2026 2025

Loss per share, diluted (GAAP) $ (0.25) $ (0.50) $ (0.99) $ (1.26)

Intangible asset impairment 0.03 0.10 0.03 0.10

Fair value adjustment of contingent consideration (0.03) — (0.03) —

Restructuring charges — 0.10 — 0.23

Tariffs 0.01 0.01 0.02 0.04

European Union Medical Device Regulation fees increase — — — —

Acquisition-related costs 0.01 0.04 0.07 0.11

Minimum purchase commitment cost — 0.01 — 0.04

Loss per share, diluted (non-GAAP) $ (0.23) $ (0.24) $ (0.90) $ (0.74)

GRAPHIC

Filename: footer.jpg · Sequence: 7

Binary file (17696 bytes)

Download footer.jpg

GRAPHIC

Filename: header.jpg · Sequence: 8

Binary file (12351 bytes)

Download header.jpg

GRAPHIC

Filename: logo.jpg · Sequence: 9

Binary file (68364 bytes)

Download logo.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.3

Cover

May 01, 2023

Cover [Abstract]

Document Type

8-K

Document Period End Date

Oct. 27, 2026

Entity Registrant Name

OrthoPediatrics Corp.

Entity Central Index Key

0001425450

Amendment Flag

false

Entity Incorporation, State or Country Code

Entity File Number

001-38242

Entity Tax Identification Number

26-1761833

Entity Address, Address Line One

2850 Frontier Drive

Entity Address, City or Town

Warsaw

Entity Address, State or Province

Entity Address, Postal Zip Code

46582

City Area Code

574

Local Phone Number

268-6379

Title of 12(b) Security

Common Stock, $0.00025 par value per share

Trading Symbol

KIDS

Security Exchange Name

NASDAQ

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Document Information [Line Items]

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration